Exosome play Evox aims for clinic with £35.5M series B

Evox Therapeutics Ltd. (Oxford, U.K.) raised on Sept. 3 £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford Sciences Innovation (OSI), Oxford University and undisclosed private investors.

Evox is developing exosome-based therapeutics, which use engineered extracellular vesicles to deliver therapies to specific tissues and areas of the body, including the CNS. Its most advanced program, which is in preclinical optimization, consists of protein replacement exosomes to treat Niemann-Pick disease type C (see "Evoking Exosomes")...